Skip to main content
SpringerLink
Log in

Managing Antipsychotic-Induced Acute and Tardive Dystonia

  • Review Article
  • Drug Safety Concept
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Antipsychotic-induced extrapyramidal adverse effects continue to be a serious problem in the treatment of psychotic disorders. While the pathophysiology of these adverse effects is not well understood, much recent research has focused on improving our ability to use available pharmacotherapy in the most effective and least toxic manner.

Acute dystonic reactions only occur within the first days of antipsychotic treatment. They are often distressing and frightening for the patient and may even be dangerous. However, they can be effectively prevented or reversed with anticholinergics. Furthermore, the growing use of the new atypical antipsychotics will lead to a significant decrease in the rate of acute dystonic reactions.

In contrast, tardive dystonia is a long-lasting menace in the course of antipsychotic treatment, for which there is no established therapy. Tardive dystonia is sometimes disabling or disfiguring and, like other tardive disorders, is potentially irreversible. Because, in most cases, patients need to continue taking the antipsychotic that has caused the adverse effect to prevent relapse of the mental illness, preventive measures are crucial. Antipsychotics should be prescribed only for patients affected by psychotic disorders, when definitely indicated and at the lowest effective dosage. The use of clozapine and other novel antipsychotic agents is also likely to represent an important step in the prevention and treatment of tardive dystonia. Compared with traditional antipsychotics, most of the new antipsychotics are characterised by a low acute extrapyramidal adverse effects liability and they also bring the hope of reducing the risk of tardive disorders. If tardive dystonia has occurred, switching to clozapine or another atypical antipsychotic and treatment with tetrabenazine, reserpine and botulinum toxin are possible options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1974; 48: 13–9

    Google Scholar 

  2. Rifkin A. Extrapyramidal side-effects: a historical perspective. J Clin Psychiatry 1987; 48 (9 Suppl.): 3–6

    PubMed  Google Scholar 

  3. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1975; 31: 62–76

    Google Scholar 

  4. Gasser T. Idiopathic, myoclonic and Dopa-responsive dystonia. Curr Opin Neurol 1997; 10: 357–62

    Article  PubMed  CAS  Google Scholar 

  5. Gasser T. Advances in the genetics of movement disorders: implications for molecular diagnosis. J Neurol 1997; 244: 341–8

    Article  PubMed  CAS  Google Scholar 

  6. Mazurek MF, Rosebush PI. Circadian pattern of acute, neuroleptic-induced dystonic reactions. Am J Psychiatry 1996; 153: 708–10

    PubMed  CAS  Google Scholar 

  7. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (4 Suppl.): 1–63

    Google Scholar 

  8. Chakos MH, Mayerhoff DI, Loebel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first-episode of schizophrenia. Psychopharmacol Bull 1992; 28: 81–6

    PubMed  CAS  Google Scholar 

  9. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994; 151: 1819–21

    PubMed  CAS  Google Scholar 

  10. Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988; 145: 1455–6

    PubMed  CAS  Google Scholar 

  11. Remington GJ, Voineskos G, Pollock B, et al. Prevalence of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1990; 147: 1231–3

    PubMed  CAS  Google Scholar 

  12. Jeanjean AP, Laterre EC, Maloteaux JM. Neuroleptic binding to sigma receptors: possible involvement in neuroleptic-induced acute dystonia. Biol Psychiatry 1997; 41: 1010–9

    Article  PubMed  CAS  Google Scholar 

  13. Ibrahim ZY, Brooks EF. Neuroleptic-induced bilateral temporomandibular joint dislocation. Am J Psychiatry 1996; 153: 293–4

    PubMed  CAS  Google Scholar 

  14. Hyman SE. Manual of psychiatric emergencies. Boston: Little, Brown and Company, 1984: 171–3

    Google Scholar 

  15. Thornton A, McKenna PJ. Acute dystonic reactions complicated by psychotic phenomena. Br J Psychiatry 1994; 164: 115–8

    Article  PubMed  CAS  Google Scholar 

  16. Magnusson A, Opjordsmoen S, Dietrichs E. Medikamentinduserte dystonier mistolket sola hysteri. Tidsskr Nor Laegeforen 1996; 116: 844–5

    PubMed  CAS  Google Scholar 

  17. Lang AE. Psychogenic dystonia: a review of 18 cases. Can J Neurol Sci 1995; 22: 136–43

    PubMed  CAS  Google Scholar 

  18. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–60

    Article  PubMed  CAS  Google Scholar 

  19. Sweet Jr C. Drug-induced dystonia. Am J Psychiatry 1975; 132: 532–4

    Google Scholar 

  20. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40: 1113–7

    Article  PubMed  CAS  Google Scholar 

  21. Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol 1987; 7: 164–6

    PubMed  CAS  Google Scholar 

  22. National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246–61

    Article  Google Scholar 

  23. DiMascio A, Demirgian E. Antiparkinson drug overuse. Psychosomatics 1970; 11: 596–601

    PubMed  CAS  Google Scholar 

  24. Swett Jr C. Drug-induced dystonia. Am J Psychiatry 1975; 132: 532–4

    PubMed  Google Scholar 

  25. Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981; 138: 1243–4

    PubMed  CAS  Google Scholar 

  26. Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology 1979; 61: 261–2

    Article  PubMed  CAS  Google Scholar 

  27. Chiles JA. Extrapyramidal reactions in adolescents treated with high-potency antipsychotics. Am J Psychiatry 1978; 135: 239–40

    PubMed  CAS  Google Scholar 

  28. Arana GW, Goff DC, Baldessarini RJ, et al. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988; 145: 993–6

    PubMed  CAS  Google Scholar 

  29. Casey DE. Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int J Psychopharmacol 1997; 12 (1 Suppl.): S19–S27

    Article  Google Scholar 

  30. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988; 145: 869–71

    PubMed  CAS  Google Scholar 

  31. Garver DL, Davis JM, Dekirmenjian H, et al. Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacology 1976; 47: 199–201

    Article  CAS  Google Scholar 

  32. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109–20

    Article  PubMed  CAS  Google Scholar 

  33. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55–72

    Article  PubMed  CAS  Google Scholar 

  34. Wong DF, Wagner Jr HN, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron emission tomography in the living human brain. Science 1984; 226: 1393–6

    Article  PubMed  CAS  Google Scholar 

  35. Casey DE. Neuroleptic-induced acute dystonia. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. New York: Futura Press, 1991: 21–40

    Google Scholar 

  36. Chiu LPW. Transient recurrence of auditory hallucinations during acute dystonia. Br J Psychiatry 1989; 155: 110–3

    Article  PubMed  CAS  Google Scholar 

  37. Gelenberg AJ. Treating extrapyramidal reactions: some current issues. J Clin Psychiatry 1987; 48 Suppl.: S24–S27

    Google Scholar 

  38. Schatzberg AF, Cole JO, De Battista C. Manual of clinical psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Press, Inc, 1997: 142–3

    Google Scholar 

  39. Korczyn AD, Goldberg GJ. Intravenous diazepam in drug-induced dystonic reactions. Br J Psychiatry 1972; 121: 75–7

    Article  PubMed  CAS  Google Scholar 

  40. Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 1978; 135: 1232–3

    PubMed  CAS  Google Scholar 

  41. World Health Organization Heads of Centres Collaborating in WHO co-ordinated studies on biological aspects of mental illness. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990; 156: 412

    Article  Google Scholar 

  42. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991; 49: 739–45

    Article  Google Scholar 

  43. Singh MM, Kay SR. Therapeutical reversal with benztropine in schizophrenics. J Nerv Ment Dis 1973; 169: 258–66

    Google Scholar 

  44. Johnstone EC, Crow TJ, Ferrier JN, et al. Adverse effects of anticholinergic medications on positive schizophrenic symptoms. Psychol Med 1983; 13: 513–27

    Article  PubMed  CAS  Google Scholar 

  45. Faulk RS, Gilmore JH, Jensen EW, et al. Risperidone-induced dystonic reaction [letter]. Am J Psychiatry 1996; 153: 577

    PubMed  CAS  Google Scholar 

  46. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40

    Article  PubMed  CAS  Google Scholar 

  47. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35

    PubMed  CAS  Google Scholar 

  48. Schatzberg AF, Cole JO, De Battista C. Manual of clinical psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Press, Inc., 1997: 162

    Google Scholar 

  49. Keegan DL, Rajput AH. Drug-induced dystonia tarda-treatment with L-dopa. Dis Nerv Systs 1973; 38: 167–9

    Google Scholar 

  50. Raja M. Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci 1995; 245: 145–51

    Article  PubMed  CAS  Google Scholar 

  51. Yassa R, Nair V, Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986; 73: 629–33

    Article  PubMed  CAS  Google Scholar 

  52. Raja M, Azzoni A. Tardive dystonia. Prevalence, risk factors and clinical features. It J Neurol Sci 1996; 17: 409–18

    Article  CAS  Google Scholar 

  53. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335–46

    Article  PubMed  CAS  Google Scholar 

  54. Yassa R, Nair NPV, Iskandar H, et al. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry 1990; 147: 1156–63

    PubMed  CAS  Google Scholar 

  55. Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991; 148: 1055–9

    PubMed  CAS  Google Scholar 

  56. Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1985; 71: 488–94

    Article  PubMed  CAS  Google Scholar 

  57. Gardos G, Cole JO, Salomaon M, et al. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987; 144: 895–902

    PubMed  CAS  Google Scholar 

  58. Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharm Bull 1986; 152: 254–8

    Google Scholar 

  59. Glazer WM, Morgenstern H, Niedzwiecki D, et al. Heterogeneity of tardive dyskinesia. Br J Psychiatry 1988; 152: 253–9

    Article  PubMed  CAS  Google Scholar 

  60. Roller WC. Tardive dystonia: diagnosis and treatment. In: Wolf ME, Mosnaim AD, editors. Tardive dyskinesia: biological mechanisms and clinical aspects. Washington, DC: American Psychiatric Press, 1988

    Google Scholar 

  61. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: 701–15

    Article  PubMed  CAS  Google Scholar 

  62. Yadalam KG, Korn ML, Simpson GM. Tardive dystonia: four case histories. J Clin Psychiatry 1990; 51: 17–20

    PubMed  CAS  Google Scholar 

  63. Chiu HF, Lee S. Tardive dystonia. Aust N Z J Psychiatry 1989; 23: 566–70

    Article  PubMed  CAS  Google Scholar 

  64. Owens DGC. Dystonia: a potential pyschiatric pitfall. Br J Psychiatry 1990; 156: 620–34

    Article  PubMed  CAS  Google Scholar 

  65. Sachdev P. Risk factors for tardive dystonia: a case-control comparison with tardive dyskinesia. Act Psychiatr Scand 1993; 88: 98–103

    Article  CAS  Google Scholar 

  66. Yassa R, Nair V, Iskander H. A comparison of severe tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1989; 80: 155–9

    Article  PubMed  CAS  Google Scholar 

  67. Inada T. Yagi G, Kamijima K, et al. A statistical trial of sub-classification for tardive dyskinesia. Acta Psychiatr Scand 1990; 82: 404–7

    Article  PubMed  CAS  Google Scholar 

  68. Casey DE, Hansen TE. Spontaneous dyskinesia. In: Jeste DV, Wyatt RJ, editors. Neuropsychiatric movement disorders. Washington, DC: American Psychiatric Press, 1984: 68–95

    Google Scholar 

  69. Casey DE, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: Can it be developed into a clinical strategy for long-term treatment? In: Bannet J, Belmaker RH, editors. New directions in tardive dyskinesia research. Basel: Karqer, 1983: 65–79

    Google Scholar 

  70. Lieberman JA, Johns C, Cooper T, et al. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 1989; 99: 54–9

    Article  Google Scholar 

  71. Fahn S. Drug treatment of hyperkinetic movement disorders. Semin Neurol 1987; 7: 192–208

    Article  PubMed  CAS  Google Scholar 

  72. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1: 193–208

    Article  PubMed  CAS  Google Scholar 

  73. Burke RE, Kang UJ. Tardive dystonia: clinical aspects and treatment. Adv Neurol 1988; 49: 199–210

    PubMed  CAS  Google Scholar 

  74. Lieberman JA, Lesser M, Johns C, et al. Pharmacologic studies of tardive dyskinesia. J Clin Psychopharmacol 1988; 8 (4 Suppl.): 575–635

    Google Scholar 

  75. Marsden CD, Quinn NP. The dystonias. BMJ 1990; 300: 139–44

    Article  PubMed  CAS  Google Scholar 

  76. Adityanjee, Jayaswal SK, Chan TM, et al. Temporary remission of tardive dystonia following electroconvulsive therapy. Br J Psychiatry 1990; 156: 433–5

    Article  PubMed  CAS  Google Scholar 

  77. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov Disord 1991; 6: 293–303

    Article  PubMed  CAS  Google Scholar 

  78. Postolache TT, Londono JH, Halem RG, et al. Electroconvulsive therapy in tardive dystonia. Convuls Ther 1995; 11: 275–9

    PubMed  CAS  Google Scholar 

  79. Kaplan Z, Benjamin J, Zohar J. Remission of tardive dystonia with ECT. Convuls Ther 1991; 7: 280–3

    PubMed  Google Scholar 

  80. Lieberman JA, Alvir J, Mukherjee S, et al. Treatment of tardive dyskinesia with bromocriptine: a test of the receptor modification strategy. Arch Gen Psychiatry 1989; 46: 908–13

    Article  PubMed  CAS  Google Scholar 

  81. Luchins D, Goldman M. High dose bromocriptine in a case of tardive dystonia. Biol Psychiatry 1985; 20: 179–81

    Article  PubMed  CAS  Google Scholar 

  82. Adityanjee, Estrera AB. Successful treatment of tardive dystonia with clozapine. Biol Psychiatry 1996; 39: 1064–5

    Article  PubMed  CAS  Google Scholar 

  83. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases. Mov Disord 1994; 9: 321–4

    Article  PubMed  CAS  Google Scholar 

  84. Shapleske J, Mickay AP, McKenna PJ. Successful treatment of tardive dystonia with clozapine a clonazepam. Br J Psychiatry 1996; 168: 516–8

    Article  PubMed  CAS  Google Scholar 

  85. Trugman JM, Leadbetter R, Zalis ME, et al. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord 1994; 9: 441–6

    Article  PubMed  CAS  Google Scholar 

  86. van Harten PN, Campus DJ, Matroos GE. Use of clozapine in tardive dystonia. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 263–74

    Article  PubMed  Google Scholar 

  87. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–10

    Article  PubMed  CAS  Google Scholar 

  88. Van Putten T, Wirshing W, Marder S. Tardive Miege syndrome responsive to clozapine. J Clin Psychopharmacol 1990; 10: 381–2

    Article  PubMed  Google Scholar 

  89. Blake LM, Marks RC, Nierman P, et al. Clozapine and clonazepam in tardive dystonia. J Clin Psychopharmacol 1991; 11: 268–9

    Article  PubMed  CAS  Google Scholar 

  90. Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv MentDis 1993; 181: 137–8

    Article  PubMed  CAS  Google Scholar 

  91. Raja M, Altavista MC, Maisto G, et al. Tardive lingual dystonia treated with clozapine. Mov Disord 1996; 11: 585–6

    Article  PubMed  CAS  Google Scholar 

  92. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55: 102–6

    PubMed  Google Scholar 

  93. Chengappa KN, Shelton MD, Baker RW, et al. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994; 55: 142–5

    PubMed  CAS  Google Scholar 

  94. Johnson CG, Littrell KH, Magill AM. Starting patients on clozapine in a partial hospitalization program. Hosp Community Psychiatry 1994; 45: 264–8

    PubMed  CAS  Google Scholar 

  95. Levkovitch Y, Kronenberg J, Kayser N, et al. Clozapine for tardive dyskinesia in adolescents. Brain Dev 1995; 17: 213–5

    Article  PubMed  CAS  Google Scholar 

  96. Kaufman DM. Use of botulinum toxin injections for spasmodic torticollis of tardive dystonia. J Neuropsychiatry Clin Neurosci 1994; 6: 50–3

    PubMed  CAS  Google Scholar 

  97. Shulman LM, Singer C, Weiner WJ. Improvement of both tardive dystonia and akathisia after botulinum toxin infection. Neurology 1996; 46: 844–5

    Article  PubMed  CAS  Google Scholar 

  98. Kiriakakis V, Bhatia K, Quinn N, et al. Botulinum toxin treatment of tardive syndromes [letter]. Mov Disord 1997; 12: 26

    Google Scholar 

  99. Jancovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186–94

    Article  Google Scholar 

  100. Szymanski S, Lieberman JA, Safferman A, et al. Rib fractures as an unusual complication of severe tardive dystonia [letter]. J Clin Psychiatry 1993; 54: 160

    PubMed  CAS  Google Scholar 

  101. Woerner M, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991; 11: 34–42

    Article  PubMed  CAS  Google Scholar 

  102. Glazer WM, Morgenstern H, Doucette JT. The prediction of chronic persistent versus intermittent tardive dyskinesia: a retrospective follow-up study. Br J Psychiatry 1991; 158: 822–8

    Article  PubMed  CAS  Google Scholar 

  103. Yassa R, Nastase C, Dupont D, et al. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 1992; 149: 1206–11

    PubMed  CAS  Google Scholar 

  104. Chiu H, Shum P, Lau J, et al. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992; 149: 1081–5

    PubMed  CAS  Google Scholar 

  105. McCreadie RG, Robertson LJ, Wiles DH. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 1992; 160: 793–9

    Article  PubMed  CAS  Google Scholar 

  106. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993; 19: 303–15

    Article  PubMed  CAS  Google Scholar 

  107. Muscettola G, Pampallona S, Barbato G, et al. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 1993; 87: 29–36

    Article  PubMed  CAS  Google Scholar 

  108. Casey DE. Affective disorders and tardive dyskinesia. Encephale 1988; 14: 221–6

    PubMed  Google Scholar 

  109. Ganzini L, Heintz RT, Hoffman WF, et al. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics: a controlled study. Arch Gen Psychiatry 1991; 48: 259–63

    Article  PubMed  CAS  Google Scholar 

  110. Ganzini L, Casey DE, Hoffman WF, et al. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull 1992; 28: 281–6

    PubMed  CAS  Google Scholar 

  111. Woemer MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993; 150: 966–8

    Google Scholar 

  112. Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33: 121–2

    Article  PubMed  CAS  Google Scholar 

  113. Duke PJ, Pantelis C, Barnes TR. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994; 164: 630–6

    Article  PubMed  CAS  Google Scholar 

  114. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874–8

    Article  PubMed  CAS  Google Scholar 

  115. Barnes TRE. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev 1987; 4: 301–19

    Google Scholar 

  116. Chouinard G, Annable L, Ross-Chouinard A, et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8: 21–6

    Article  Google Scholar 

  117. Annable L, Chouinard G, Ross-Chouinard A, et al. The relationship between neuroleptic-induced parkinsonism and tardive dyskinesia. Biol Psychiatry 1991; 29: 210–329S

    Google Scholar 

  118. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia: incidence in the elderly. JAMA 1991; 266: 2402–6

    Article  PubMed  CAS  Google Scholar 

  119. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk-factors. J Clin Psychopharmacol 1988; 8: 525–65

    Article  Google Scholar 

  120. Keepers GA, Casey DE. Use of neuroleptic induced extrapyramidal symptoms to predict future vulnerability to side-effects. Am J Psychiatry 1991; 148: 85–9

    PubMed  CAS  Google Scholar 

  121. Sandyk R, Kay SR. Edentulousness and neuroleptic-induced neck and trunk dyskinesia. Funct Neurol 1990; 5: 361–3

    PubMed  CAS  Google Scholar 

  122. Chiu HF, Leung JY, Lee S. Tardive dystonia in Chinese. Singapore Med J 1989; 30: 441–3

    PubMed  CAS  Google Scholar 

  123. Sachdev P. Clinical characteristics of 15 patients with tardive dystonia. Am J Psychiatry 1993; 150: 498–500

    PubMed  CAS  Google Scholar 

  124. Cooper SJ, Doherty MM, King DJ. Tardive dystonia: the benefits of time. Br J Psychiatry 1989; 155: 113–5

    Article  PubMed  CAS  Google Scholar 

  125. Crane GE, Naranjo ER. Motor disorders induced by neuroleptics. Arch Gen Psychiatry 1971; 24: 179–84

    Article  PubMed  CAS  Google Scholar 

  126. Friedman JH, Kuraski LT, Wagner RI. Tardive dystonia in a psychiatric hospital. J Neurol Neurosur Psychiatry 1987; 50: 801–3

    Article  CAS  Google Scholar 

  127. Sachdev P. The prevalence of tardive dystonia in patients with chronic schizophrenia. Aust NZJ Psychiatry 1991; 25: 446–8

    CAS  Google Scholar 

  128. van Harten PN, Matroos GE, Hoek HW, et al. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Caracas Extrapyramidal Syndromes Study: I. Schizophr Res 1996; 19: 195–203

    Article  PubMed  Google Scholar 

  129. Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord 1990; 5: 319–21

    Article  PubMed  CAS  Google Scholar 

  130. Micheli F, Fernandez Pardal M, Gatto M, et al. Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol 1993; 16: 315–23

    Article  PubMed  CAS  Google Scholar 

  131. Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. Neurology 1994; 44: 2115–9

    Article  PubMed  CAS  Google Scholar 

  132. Hoffman WF, Casey DE. Computed tomographic evaluation of patients with tardive dyskinesia. Schizophr Res 1991; 5: 1–12

    Article  PubMed  CAS  Google Scholar 

  133. Jawed SH, Singh I. Tardive dyskinesia with schizophrenic relapse. J Ment Defic Res 1989; 33: 331–4

    PubMed  Google Scholar 

  134. Sachdev P. Depression-dependent exacerbation of tardive dyskinesia. Br J Psychiatry 1989; 155: 253–5

    Article  PubMed  CAS  Google Scholar 

  135. Sandyk R, Pardeshi R. Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin. Int J Neurosci 1990; 50: 215–21

    Article  PubMed  CAS  Google Scholar 

  136. Yazici O, Kantemir E, Tastaban Y, et al. Spontaneous improvement of tardive dystonia during mania. Br J Psychiatry 1991; 158: 847–50

    Article  PubMed  CAS  Google Scholar 

  137. Hide TM, Egan MF, Brown RJ, et al. Diurnal variation in tardive dyskinesia. Psychiatry Res 1995; 56: 53–7

    Article  Google Scholar 

  138. Tan CH, Chiang PC, Ng LL, et al. Oculogyric spasm in Asian psychiatric in-patients on maintenance medication. Br J Psychiatry 1994; 165: 381–3

    Article  PubMed  CAS  Google Scholar 

  139. Schooler N, Kane JM. Research diagnoses for tardive dyskinesia. Acta Psychiatr Scand 1982; 39: 486–7

    CAS  Google Scholar 

  140. Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): NIMH Psychopharmacology Research Branch, 1976

    Google Scholar 

  141. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull 1991; 17: 31–24

    Article  Google Scholar 

  142. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  143. Baldessarini RJ, Frankeburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324: 746–54

    Article  PubMed  CAS  Google Scholar 

  144. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54: 327–30

    PubMed  CAS  Google Scholar 

  145. Gerlach J, Peacock L. Motor and mental side-effects of clozapine. J Clin Psychiatry 1994; 55: 107–9

    PubMed  Google Scholar 

  146. Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side-effects. Psychopharmacology 1996; 124: 188–96

    Article  PubMed  CAS  Google Scholar 

  147. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295–305

    Article  PubMed  CAS  Google Scholar 

  148. Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol [abstract]. Clin Neuropharmacol 1992; 15 (1 Suppl.): 90A

    Article  PubMed  Google Scholar 

  149. Woerner MG, Sheitman BB, Lieberman JA, et al. Tardive dyskinesia induced by risperidone [letter]? Am J Psychiatry 1996; 153: 843

    PubMed  CAS  Google Scholar 

  150. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disorders 1997; 12: 119–21

    Article  CAS  Google Scholar 

  151. Rangwani SR, Gupta S, Burke WJ, et al. Improvement of debilitating tardive dyskinesia with risperidone. Ann Clin Psychiatry 1996; 8: 27–9

    Article  PubMed  CAS  Google Scholar 

  152. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15 (1 Suppl.): S36–44

    Article  Google Scholar 

  153. Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet 1996; 347: 127–8

    Article  PubMed  CAS  Google Scholar 

  154. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213–8

    PubMed  CAS  Google Scholar 

  155. Keltner NL. Risperidone: the search for a better antipsychotic. Perspect Psychiatr Care 1995; 31: 30–3

    Google Scholar 

  156. Kopala LC, Honer WG. The use of risperidone in severely demented patients with persistent vocalizations. MDE Ed J 1997; 12: 73–7

    CAS  Google Scholar 

  157. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients. J Clin Psychiatry 1995; 56: 514–8

    PubMed  CAS  Google Scholar 

  158. Adler A, Angrist B, Reiter S, et al. Neuroleptic-induced akathisia: a review. Psychopharmacology 1989; 42: 872–4

    Google Scholar 

  159. Hanin B, Lerner Y, Srour N. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia. Convuls Ther 1995; 11: 271–4

    PubMed  CAS  Google Scholar 

  160. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double blind, prospective trial of high dosage trihexyphenidyl. Neurology 1986; 36: 160–4

    Article  PubMed  CAS  Google Scholar 

  161. Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988; 3: 46–60

    Article  PubMed  CAS  Google Scholar 

  162. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABA mimetic strategy. Am J Psychiatry 1990; 147: 445–51

    PubMed  CAS  Google Scholar 

  163. Jancovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38: 391–4

    Article  Google Scholar 

  164. Jankovic J, Beach J. Long term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358–62

    Article  PubMed  CAS  Google Scholar 

  165. Dorevitch A, Kalian M, Shlafman M, et al. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 1997; 41: 114–6

    Article  PubMed  CAS  Google Scholar 

  166. Elkashef AM, Ruskin PE, Bacher N, et al. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry 1990; 147: 505–6

    PubMed  CAS  Google Scholar 

  167. Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149: 773–7

    PubMed  CAS  Google Scholar 

  168. Peet M, Laugharne J, Rangarajan N, et al. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993; 8: 151–3

    Article  PubMed  CAS  Google Scholar 

  169. Akhtar S, Jajor TR, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med 1993; 39: 124–6

    PubMed  CAS  Google Scholar 

  170. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405–7

    PubMed  CAS  Google Scholar 

  171. Dabiri LM, Pasta D, Darby JK, et al. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 1994; 151: 925–6

    PubMed  CAS  Google Scholar 

  172. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57: 167–73

    PubMed  CAS  Google Scholar 

  173. Shriqui CL, Bradwejn J, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992; 149: 391–3

    PubMed  CAS  Google Scholar 

  174. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992; 15: 276–88

    Article  PubMed  CAS  Google Scholar 

  175. Cates M, Lusk K, Wells BG. Are calcium-channel blockers effective in the treatment of tardive dyskinesia? Ann Pharmacother 1993; 27: 191–6

    PubMed  CAS  Google Scholar 

  176. Abad V, Osview F. Treatment of persistent myoclonic tardive dystonia with verapamil. Br J Pyschiatry 1993; 162: 554–6

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servizio Psichiatrico di Diagnosi e Cura, Dipartimento di Salute Mentale, Ospedale Santo Spirito, Via Prisciano 26, CAP 00136, Rome, Italy

    Michele Raja

Authors
  1. Michele Raja
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Raja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raja, M. Managing Antipsychotic-Induced Acute and Tardive Dystonia. Drug-Safety 19, 57–72 (1998). https://doi.org/10.2165/00002018-199819010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199819010-00005

Keywords

Search

Navigation